Anaxomics' TPMS technology offers valuable insights for molecularly comparing different drugs, enabling the identification of the main strengths of a drug over the standards of care or other competitors. This provides a rationale for investment decisions based on predicted clinical performance, complementing market strategies and commercial considerations, and ensuring a comprehensive assessment for optimal decision-making
What does Anaxomics offer?
Gaining Comprehensive Insights into Therapeutic Options
In the field of drug discovery and development, it is crucial to accurately assess the efficacy and safety of your drug compared to competitors. Anaxomics’ TPMS technology, offers an advanced solution for conducting comprehensive analyses that evaluate the strength of different therapeutic options while providing a deeper understanding of the underlying molecular mechanisms that contribute to their effectiveness.
Enhanced Molecular Mechanism Understanding
Anaxomics' TPMS technology is designed to unravel the intricate molecular mechanisms that drive the strength of each therapeutic option, providing valuable insights for further optimization and development and ultimately paving the way for advancements towards personalized medicine (Carcereny, 2021; Segú-Vergés, 2021).
By utilizing Anaxomics' TPMS technology, researchers and pharmaceutical companies can improve their decision-making process by obtaining comprehensive and detailed information about the comparative strengths of therapeutic options. This enables them to make informed choices in drug development, leading to more effective treatments and improved patient outcomes.
First image shows an in silico head to head comparison between alectinib and brigatinib from the study performed in collaboration with Catalan Institute of Oncology B-ARGO Group, Hospital Germans Trias i Pujol, Takeda Farmacéutica (Spain), Universitat Pompeu Fabra and Anaxomics Biotech (Carcereny, 2021). The second image represents an in silico head to head comparison between canakinumab and tocilizumab, study performed in collaboration with University Children's Hospital (Münster, Germany), Novartis (Amsterdam, Netherlands), Novartis (Barcelona, Spain) and Anaxomics Biotech (Barcelona, Spain) (Segú-Vergés, 2021).
- Carcereny, E., A. Fernández-Nistal, A. López, C. Montoto, A. Naves,C. Segú-Vergés, M. Coma, G.
Jorba, B. Oliva and J. M. Mas (2021). Head to head evaluation of second generation ALK inhibitors
brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems
biology-based approach. Oncotarget, 12(4): p. 316-332.
- Segú-Vergés, C., M. Coma, C. Kessel, S. Smeets, D. Foell and A. Aldea (2021). Application of
systems biology-based in silico tools to optimize treatment strategy identification in Still's
disease. Arthritis Res Ther, 23(1): p. 126.